Levofloxacin

ArtNr	HY-B0330-5g
Hersteller	MedChem Express
CAS-Nr.	100986-85-4
Menge	5 g
Quantity options	100 mg 10 mM/1 mL 5 g
Kategorie	Food Safety Antibiotics Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]Drlica K, et al. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev. 1997 Sep;61(3):377-92. \|[2]Smee DF, et al. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003 Jan;57(1-2):41-52.\|[3]Rand A, et al. Effect of levofloxacin on some body tissues in mice. Effect of levofloxacin on some body tissues in mice. Iraqi Journal of Veterinary Sciences, 2021.\|[4]JI B, et al. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4. ACS Infect Dis. 2024 Apr 12;10(4):1327-1338. Acta Pharm Sin B. 2025 Sep 19. AMB Express. 2024 Dec 24;14(1):141. Antibiotics (Basel). 2022 Feb 1;11(2):192. Antimicrob Agents Chemother. 2021 Feb 17;65(3):e01921-20. bioRxiv. 2024 May 10. bioRxiv. 2025 January 19. Cell Rep Methods. 2023 Oct 23;3(10):100599. Chin J Traumatol. 2024 Jul 3:S1008-1275(24)00075-0. Clin Chem. 2019 Dec;65(12):1522-1531. Commun Biol. 2025 Oct 6;8(1):1425. Diagn Microbiol Infect Dis. 2025 Nov 4;114(2):117181. EBioMedicine. 2025 May 30:117:105776. Eur J Clin Microbiol Infect Dis. 2025 Sep 29. Future Microbiol. 2025 Oct 13:1-10. Infect Genet Evol. 2025 Sep:133:105780. Int J Antimicrob Agents. 2025 Jun 9:107551. Microbiol Spectr. 2025 May 19:e0307424. Microbiol Spectr. 2025 Oct 15:e0122125. Nat Commun. 2025 May 10;16(1):4366. PLoS One. 2024 Apr 18;19(4):e0298577. Res Sq. 2025 Aug 05. Results Chem. 2024 Oct. SSRN. 2025 Oct 14. Toxics. 2025 Feb 5;13(2):122. Water. 2025 Jun 6. Emerg Microbes Infect. 2024 Dec;13(1):2321981. J Med Virol. 2025 Oct;97(10):e70655. Nat Commun. 2022 Mar 2;13(1):1116.
Smiles	O=C(C(C1=O)=CN2[C@@H](C)COC3=C(N4CCN(C)CC4)C(F)=CC1=C23)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(-)-Ofloxacin
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-anti-virus
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Antibiotic; Bacterial; DNA/RNA Synthesis; Orthopoxvirus; Topoisomerase
Manufacturer - HS Code	H302, H317, H334, H361, H362
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	361.37
Product Description	Levofloxacin ((-)-Ofloxacin) is an orally active antibiotic and is active against both Gram-positive and Gram-negative bacteria. Levofloxacin inhibits the DNA gyrase and topoisomerase IV. Levofloxacin can be used for chronic periodontitis, airway inflammation and BK Viremia research. Levofloxacin shows anti-orthopoxvirus activity[1][2][3][4][5].
Manufacturer - Research Area	Infection; Cancer
Solubility	DMSO : 10 mg/mL (ultrasonic)\|H2O : ≥ 5 mg/mL
Manufacturer - Pathway	Anti-infection; Cell Cycle/DNA Damage
Clinical information	Launched
Isoform	Quinolone; Topoisomerase
UNSPSC Code	12352005
Precautionary	H302, H317, H334, H361, H362

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.